Market Jitters: U.S. Stocks and Oil Rise Amidst Tensions wit...
06 Apr 2026
Saptak Chem & Business Limited announced the successful allotment of 20,00,000 fully paid-up equity shares following the conversion of warrants by non-promoter investors. The Board of Directors approved this allotment during their meeting held on April 06, 2026, marking a significant capital expansion for the Ahmedabad-based company.
Warrant Conversion Details
The allotment involved four non-promoter investors who exercised their right to convert share warrants into equity shares. Each investor converted 5,00,000 warrants, with the conversion completed upon payment of the remaining exercise price.
Allottee Category Warrants Converted Post-Allotment Shareholding (%) Akshay Shah HUF Non-Promoter, Others 5,00,000 16.27% Jayshree Jain Non-Promoter, Individual 5,00,000 16.27% HMM Consultancy LLP Non-Promoter, Others 5,00,000 16.27% Ankush Agarwal HUF Non-Promoter, Others 5,00,000 16.27% Total 20,00,000 65.08%
Financial Impact
The warrant conversion generated Rs.1,57,50,000 for the company through the collection of the remaining exercise price of Rs.7.875/- per warrant. This amount represents 75% of the total warrant exercise price of Rs.10.50/- per warrant, with the initial 25% having been paid during the original warrant allotment on January 13, 2026.
Financial Parameter Amount Exercise Price per Warrant Rs.7.875/- Total Consideration Received Rs.1,57,50,000/- Face Value per Share Rs.10/- Issue Price per Warrant Rs.10.50/-
Capital Structure Changes
The allotment significantly expanded the company's equity base, with the paid-up capital increasing substantially following the warrant conversion.
Capital Structure Before Allotment After Allotment Paid-up Capital Rs.1,07,32,270/- Rs.3,07,32,270/- Number of Equity Shares 10,73,227 30,73,227 Face Value per Share Rs.10/- Rs.10/-
Outstanding Warrants Status
Following this conversion, the company maintains a substantial number of outstanding warrants available for future conversion.
Warrant Status Number of Warrants Total Warrants Allotted (January 13, 2026) 40,00,000 Warrants Converted (April 06, 2026) 20,00,000 Outstanding Warrants 20,00,000
The remaining 20,00,000 warrants can be converted into an equal number of equity shares by paying Rs.7.875/- per warrant within 18 months from the original allotment date of January 13, 2026. The newly allotted equity shares rank pari passu with existing equity shares in all respects, providing equal rights and privileges to the new shareholders.
Saptak Chem & Business Limited has announced the resignation of its Independent Director Mr. Chirag Nanavati, effective March 13, 2026. The resignation was formally accepted during a board meeting held on the same date, as disclosed under Regulation 30 of SEBI listing regulations following BSE's directive dated March 14, 2026.
Board Meeting and Regulatory Compliance
The board meeting was conducted on March 13, 2026, from 4:30 p.m. to 5:00 p.m., where directors addressed key governance matters. The company submitted a fresh announcement to BSE Limited in compliance with SEBI Circular No: SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.
Meeting Parameter: Details Date: March 13, 2026 Duration: 4:30 p.m. to 5:00 p.m. Key Decision: Acceptance of Independent Director resignation Director Name: Mr. Chirag Nanavati DIN: 08196966 Scrip Code: 506906
Committee Positions and Responsibilities
Mr. Nanavati held significant positions within the company's governance structure. His resignation encompasses multiple key roles including Chairman of the Audit Committee, Stakeholder Relationship Committee, and Member of the Nomination and Remuneration Committee.
Position: Role Primary Role: Independent Director Audit Committee: Chairman Stakeholder Relationship Committee: Chairman Nomination and Remuneration Committee: Member Other Directorships: Novyra Pharmachem Limited, Devrup Trading Limited
Resignation Details and Confirmation
In his resignation letter dated March 13, 2026, Mr. Nanavati cited pre-occupation in other activities as the primary reason for stepping down. He expressed gratitude to the board for their cooperation during his tenure and wished the company continued success in future endeavors.
The director has confirmed that there are no material reasons for his resignation other than those mentioned in his resignation letter. Mr. Nanavati also holds directorships in two other listed entities: Novyra Pharmachem Limited and Devrup Trading Limited, both as Independent Director.
Corporate Governance Impact
The company has fulfilled its disclosure obligations by providing comprehensive details as required under SEBI regulations. The resignation represents a routine corporate governance change, with the company maintaining its commitment to regulatory transparency and proper board composition management. The company has requested Form DIR-12 to be filed with the Registrar of Companies for official record.
We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.
Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.
